Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + docetaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of sorafenib (a multi-kinase inhibitor), docetaxel (a cytotoxic chemotherapy agent), and carboplatin (an alkylating agent). The combination has been studied in clinical trials for various cancers. Sorafenib inhibits multiple intracellular and cell surface kinases involved in tumor cell signaling, proliferation, angiogenesis, and apoptosis, including Raf kinases, VEGFR, PDGFR-β, KIT, and FLT-3. Docetaxel and carboplatin are cytotoxic chemotherapy agents commonly used in cancer treatment.
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)BRAF V600ERAF1 (c-Raf-1 (Y340D/Y341D))DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + docetaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + docetaxel + carboplatin.